Supramaximal resection (SMR) has arisen as a possible surrogate to gross-total resection (GTR) to improve survival in newly diagnosed glioblastoma (nGBM). However, SMR has traditionally been limited to noneloquent regions and its feasibility in eloquent nGBM remains unclear. The authors conducted a retrospective multivariate propensity-matched analysis comparing survival outcomes for patients with left-sided eloquent nGBM undergoing SMR versus GTR.
A retrospective review was performed of all patients at our institution who underwent SMR or GTR of a left-sided eloquent nGBM during the period from 2011 to 2020. All patients underwent some form of preoperative or intraoperative functional mapping and underwent awake or asleep craniotomy (craniotomy under general anesthesia); however, awake craniotomy was performed in the majority of patients and the focus of the study was SMR achieved via awake craniotomy and functional mapping with lesionectomy and additional peritumoral fluid attenuated inversion recovery (FLAIR) resection. Propensity scores were generated controlling for age, tumor location, and preoperative Karnofsky Performance Status (KPS) score with the nearest-neighbor algorithm.
A total of 102 patients (48 SMR, 54 GTR) were included in this study. The median overall survival (OS) and progression-free survival (PFS) for patients receiving SMR were 22.9 and 5.1 months, respectively. Propensity matching resulted in a final cohort of 27 SMR versus 27 GTR patients. SMR conferred improved OS (21.55 vs 15.49 months, p = 0.0098) and PFS (4.51 vs 3.59 months, p = 0.041) compared to GTR. There was no significant difference in postoperative complication rates or KPS score in SMR compared with GTR patients (p = 0.236 and p = 0.736, respectively). In patients receiving SMR, improved OS and PFS showed a dose-dependent relationship with extent of FLAIR resection (EOFR) on log-rank test for trend (p < 0.001).
SMR by means of awake craniotomy with functional mapping for left-sided eloquent nGBM is safe and confers a survival benefit compared to GTR obtained with lesionectomy alone while preserving postoperative neurological integrity. When tolerated, greater EOFR with SMR may be associated with improved survival.
INCLUDE WHEN CITING Published online May 27, 2022; DOI: 10.3171/2022.3.JNS212399.
Disclosures Dr. Ivan holds a grant from the Office of the Provost at the University of Miami in association with Magic Leap (Plantation, Florida) augmented reality application development for neurosurgery and reports being a consultant to and receiving research funding from Medtronic and the NX Development Corp. Dr. Eichberg is supported by a grant from the National Cancer Institute (NCI; T32 CA 211034). No federal funds or funds from nongovernmental sources were used to fund the project. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
KorjaM, RajR, SeppäK, Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland. Neuro Oncol. 2019;21(3):370–379.10.1093/neuonc/noy164)| false
MarkoNF, WeilRJ, SchroederJL, LangFF, SukiD, SawayaRE. Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol. 2014;32(8):774–782.
MarkoNF, WeilRJ, SchroederJL, LangFF, SukiD, SawayaRE. Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol. 2014;32(8):774–782.2451601010.1200/JCO.2013.51.8886)| false
LacroixM, Abi-SaidD, FourneyDR, A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190–198.1178088710.3171/jns.2001.95.2.0190)| false
ChaichanaKL, Jusue-TorresI, Navarro-RamirezR, et al.Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol. 2014;16(1):113–122.
DimouJ, BelandB, KellyJ. Supramaximal resection: a systematic review of its safety, efficacy and feasibility in glioblastoma. J Clin Neurosci. 2020;72:328–334.3186483010.1016/j.jocn.2019.12.021)| false
ChangEF, ClarkA, JensenRL, Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. J Neurosurg. 2009;111(2):203–210.1926753610.3171/2009.2.JNS081101)| false
LeaoDJ, CraigPG, GodoyLF, LeiteCC, PoliceniB. Response Assessment in Neuro-Oncology criteria for gliomas: practical approach using conventional and advanced techniques. AJNR Am J Neuroradiol. 2020;41(1):10–20.
LeaoDJ, CraigPG, GodoyLF, LeiteCC, PoliceniB. Response Assessment in Neuro-Oncology criteria for gliomas: practical approach using conventional and advanced techniques. AJNR Am J Neuroradiol. 2020;41(1):10–20.3185732210.3174/ajnr.A6358)| false
HöllerhageHG, ZumkellerM, BeckerM, DietzH. Influence of type and extent of surgery on early results and survival time in glioblastoma multiforme. Acta Neurochir (Wien). 1991;113(1-2):31–37.166595010.1007/BF01402111)| false
LiYM, SukiD, HessK, SawayaR. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection?. J Neurosurg. 2016;124(4):977–988.2649594110.3171/2015.5.JNS142087)| false
PessinaF, NavarriaP, CozziL, et al.Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. J Neurooncol. 2017;135(1):129–139.
PessinaF, NavarriaP, CozziL, Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. J Neurooncol. 2017;135(1):129–139.10.1007/s11060-017-2559-9)| false
MuL, WangY, WangY, Tumor location and survival outcomes in adult patients with supratentorial glioblastoma by levels of toll-like receptor 9 expression. World Neurosurg. 2017;97:279–283.2774407810.1016/j.wneu.2016.10.015)| false
LiHY, SunCR, HeM, YinLC, DuHG, ZhangJM. Correlation between tumor location and clinical properties of glioblastomas in frontal and temporal lobes. World Neurosurg. 2018;112:e407–e414.2935580910.1016/j.wneu.2018.01.055)| false